AponeurinAlternative Names: Aponeurin
Latest Information Update: 25 Jan 2011
At a glance
- Originator Neuraxo Biopharmaceuticals
- Mechanism of Action Collagen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 25 Jan 2011 No development reported - Preclinical for Stroke in Germany (unspecified route)
- 29 Jul 2005 Aponeurin is available for licensing or partnering(http://www.neuraxo.com)
- 18 Apr 2005 Preclinical trials in Stroke in Germany (unspecified route)